Literature DB >> 24428821

Metformin induces PGC-1α expression and selectively affects hepatic PGC-1α functions.

Sanna-Mari Aatsinki1, Marcin Buler, Henriikka Salomäki, Markku Koulu, Petr Pavek, Jukka Hakkola.   

Abstract

BACKGROUND AND
PURPOSE: The objective of this study was to determine how the AMPK activating antidiabetic drug metformin affects the major activator of hepatic gluconeogenesis, PPARγ coactivator 1α (PGC-1α) and liver functions regulated by PGC-1α. EXPERIMENTAL APPROACH: Mouse and human primary hepatocytes and mice in vivo were treated with metformin. Adenoviral overexpression, siRNA and reporter gene constructs were used for mechanistic studies. KEY
RESULTS: Metformin increased PGC-1α mRNA and protein expression in mouse primary hepatocytes. 5-Aminoimidazole-4-carboxamide ribonucleotide (AICAR) (another AMPK activator) had the opposite effect. Metformin also increased PGC-1α in human primary hepatocytes; this effect of metformin was abolished by AMPK inhibitor compound C and sirtuin 1 siRNA. AMPK overexpression by AMPK-Ad also increased PGC-1α. Whereas metformin increased PGC-1α, it down-regulated gluconeogenic genes phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase). Furthermore, metformin attenuated the increase in PEPCK and G6Pase mRNAs induced by PGC-1α overexpression, but did not affect PGC-1α-mediated induction of mitochondrial genes. Metformin down-regulated several key transcription factors that mediate the effect of PGC-1α on gluconeogenic genes including Krüppel-like factor 15, forkhead box protein O1 and hepatocyte NF 4α, whereas it increased nuclear respiratory factor 1, which is involved in PGC-1α-mediated regulation of mitochondrial proteins. CONCLUSIONS AND IMPLICATIONS: Down-regulation of PGC-1α is not necessary for suppression of gluconeogenic genes by metformin. Importantly, metformin selectively affects hepatic PGC-1α-mediated gene regulation and prevents activation of gluconeogenesis, but does not influence its regulation of mitochondrial genes. These results identify selective modulation of hepatic PGC-1α functions as a novel mechanism involved in the therapeutic action of metformin.
© 2014 The British Pharmacological Society.

Entities:  

Keywords:  AMPK; G6Pase; PEPCK; PGC-1α; SIRT1; gluconeogenesis; liver; metformin

Mesh:

Substances:

Year:  2014        PMID: 24428821      PMCID: PMC3997275          DOI: 10.1111/bph.12585

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  43 in total

Review 1.  Minireview: the PGC-1 coactivator networks: chromatin-remodeling and mitochondrial energy metabolism.

Authors:  Jiandie D Lin
Journal:  Mol Endocrinol       Date:  2008-11-13

2.  Hepatocyte nuclear factor-4alpha regulates the human apolipoprotein AV gene: identification of a novel response element and involvement in the control by peroxisome proliferator-activated receptor-gamma coactivator-1alpha, AMP-activated protein kinase, and mitogen-activated protein kinase pathway.

Authors:  Xavier Prieur; Frank G Schaap; Hervé Coste; Joan C Rodríguez
Journal:  Mol Endocrinol       Date:  2005-07-28

3.  Metformin increases the PGC-1alpha protein and oxidative enzyme activities possibly via AMPK phosphorylation in skeletal muscle in vivo.

Authors:  Masataka Suwa; Toru Egashira; Hiroshi Nakano; Haruka Sasaki; Shuzo Kumagai
Journal:  J Appl Physiol (1985)       Date:  2006-08-10

4.  Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells.

Authors:  Ryan J O Dowling; Mahvash Zakikhani; I George Fantus; Michael Pollak; Nahum Sonenberg
Journal:  Cancer Res       Date:  2007-11-15       Impact factor: 12.701

5.  Dose translation from animal to human studies revisited.

Authors:  Shannon Reagan-Shaw; Minakshi Nihal; Nihal Ahmad
Journal:  FASEB J       Date:  2007-10-17       Impact factor: 5.191

6.  Coactivator PGC-1alpha regulates the fasting inducible xenobiotic-metabolizing enzyme CYP2A5 in mouse primary hepatocytes.

Authors:  Satu Arpiainen; Sanna-Mari Järvenpää; Aki Manninen; Pirkko Viitala; Matti A Lang; Olavi Pelkonen; Jukka Hakkola
Journal:  Toxicol Appl Pharmacol       Date:  2008-06-17       Impact factor: 4.219

7.  Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP.

Authors:  Yong Deuk Kim; Keun-Gyu Park; Yong-Soo Lee; Yun-Yong Park; Don-Kyu Kim; Balachandar Nedumaran; Won Gu Jang; Won-Jea Cho; Joohun Ha; In-Kyu Lee; Chul-Ho Lee; Hueng-Sik Choi
Journal:  Diabetes       Date:  2007-10-01       Impact factor: 9.461

Review 8.  Structure and function of AMP-activated protein kinase.

Authors:  J S Oakhill; J W Scott; B E Kemp
Journal:  Acta Physiol (Oxf)       Date:  2009-02-20       Impact factor: 6.311

9.  AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha.

Authors:  Sibylle Jäger; Christoph Handschin; Julie St-Pierre; Bruce M Spiegelman
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-03       Impact factor: 11.205

10.  Prenatal metformin exposure in mice programs the metabolic phenotype of the offspring during a high fat diet at adulthood.

Authors:  Henriikka Salomäki; Laura H Vähätalo; Kirsti Laurila; Norma T Jäppinen; Anna-Maija Penttinen; Liisa Ailanen; Juan Ilyasizadeh; Ullamari Pesonen; Markku Koulu
Journal:  PLoS One       Date:  2013-02-15       Impact factor: 3.240

View more
  28 in total

1.  Berberine inhibits hepatic gluconeogenesis via the LKB1-AMPK-TORC2 signaling pathway in streptozotocin-induced diabetic rats.

Authors:  Shu-Jun Jiang; Hui Dong; Jing-Bin Li; Li-Jun Xu; Xin Zou; Kai-Fu Wang; Fu-Er Lu; Ping Yi
Journal:  World J Gastroenterol       Date:  2015-07-07       Impact factor: 5.742

Review 2.  Modulation of Reactive Oxygen Species Homeostasis as a Pleiotropic Effect of Commonly Used Drugs.

Authors:  Carolin Thomas; Lia Wurzer; Ernst Malle; Michael Ristow; Corina T Madreiter-Sokolowski
Journal:  Front Aging       Date:  2022-06-14

3.  Metformin modulates mitochondrial function and mitophagy in peripheral blood mononuclear cells from type 2 diabetic patients.

Authors:  Aranzazu M de Marañón; Pedro Díaz-Pozo; Francisco Canet; Noelia Díaz-Morales; Zaida Abad-Jiménez; Sandra López-Domènech; Teresa Vezza; Nadezda Apostolova; Carlos Morillas; Milagros Rocha; Víctor M Víctor
Journal:  Redox Biol       Date:  2022-05-17       Impact factor: 10.787

4.  Metformin activates AMP-activated protein kinase by promoting formation of the αβγ heterotrimeric complex.

Authors:  Shumei Meng; Jia Cao; Qiyi He; Lishou Xiong; Evan Chang; Sally Radovick; Fredric E Wondisford; Ling He
Journal:  J Biol Chem       Date:  2014-12-23       Impact factor: 5.157

Review 5.  Benefits of Metformin in Attenuating the Hallmarks of Aging.

Authors:  Ameya S Kulkarni; Sriram Gubbi; Nir Barzilai
Journal:  Cell Metab       Date:  2020-04-24       Impact factor: 27.287

Review 6.  Metformin and cognition from the perspectives of sex, age, and disease.

Authors:  Kiran Chaudhari; Conner D Reynolds; Shao-Hua Yang
Journal:  Geroscience       Date:  2020-01-02       Impact factor: 7.713

Review 7.  Metabolic aspects in NAFLD, NASH and hepatocellular carcinoma: the role of PGC1 coactivators.

Authors:  Elena Piccinin; Gaetano Villani; Antonio Moschetta
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-03       Impact factor: 46.802

8.  Antioxidant Therapy: Is it your Gateway to Improved Cardiovascular Health?

Authors:  M Ruhul Abid; Frank W Sellke
Journal:  Pharm Anal Acta       Date:  2015-01

Review 9.  Beneficial Effects of Exogenous Ketogenic Supplements on Aging Processes and Age-Related Neurodegenerative Diseases.

Authors:  Zsolt Kovács; Brigitta Brunner; Csilla Ari
Journal:  Nutrients       Date:  2021-06-26       Impact factor: 5.717

Review 10.  Role of mitochondria in nonalcoholic fatty liver disease.

Authors:  Fatiha Nassir; Jamal A Ibdah
Journal:  Int J Mol Sci       Date:  2014-05-15       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.